Novartis Acquires US Cancer Researcher CoStim
International Business Times
Published Feb 17, 2014 06:59AM ET
By Sneha Shankar - Swiss drug maker Novartis (NYSE:NVS) said in a statement on Monday that it will acquire CoStim Pharmaceuticals, a privately-held Massachusetts-based biotechnology company, to broaden its cancer immunotherapy research program.
CoStim's main field of research, which focuses on producing antibody agents that prevent immune-blocking signals from cancer, is expected to reach annual sales of $35 billion, according to a news report by Bloomberg. The terms of the acquisition were not disclosed.
“Therapy for many types of cancers are expected to increasingly rely upon rational combinations of agents,” Mark Fishman, president of Novartis Institutes for BioMedical Research, said in a statement.
This acquisition will add to several programs that Novartis has for cancer therapies including a chimeric antigen receptor or CAR technology being developed in collaboration with the University of Pennsylvania. With this deal, Novartis is targeting PD-1, which is reportedly the next big target for cancer.
Immunotherapy involves coaxing patients’ immune cells to recognize and attack their tumors. This technology is reportedly the latest frontier of cancer research following tried and tested methods such as chemotherapy, radiation and surgery.
Companies like Bristol-Myers Squibb (NYSE:BMY), Merck (NYSE:MRK) and Roche (OTCMKTS:RHHBY) are working to use the human immune system to coordinate a powerful attack on cancer. And, for Novartis, the deal with CoStim will strengthen the company's hold over cancer immunotherapy discovery and will add to its CAR technology.
“Immunotherapy agents provide additional arrows in our quiver for such combinations. They complement our extensive portfolio of drugs that hit genetically-defined cancer-causing pathways, and also may be relevant to expansion of CAR therapies,” Fishman said.
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.